Study guide

3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

Key Takeaways Explain This Topic AI

Chorionic villus sampling (CVS) obtains placental villi, typically at about 10–13 weeks; amniocentesis obtains amniotic fluid with fetal cells, typically from about 15–18+ weeks

Both procedures enable diagnostic chromosomal (karyotype/CMA) and molecular testing; choice hinges on timing needs, test menu, and counseling about placental vs fetal tissue

Modern procedure-related miscarriage risk estimates are lower than older historical figures often quoted as ~1% for CVS and ~0.5% for amniocentesis; counsel with current center/society estimates and operator experience

CVS can detect confined placental mosaicism; mosaic CVS results often lead to follow-up amniocentesis to clarify fetal status

Genetic counselors obtain informed consent covering purpose, alternatives (including declining), residual risk of missed diagnoses outside the assay, and result pathways—including uncertain/mosaic findings

Last updated: August 2026

3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

Quick Answer: CVS (≈10–13 weeks) biopsies chorionic villi (placenta) ; amniocentesis (≈15–18+ weeks) samples amniotic fluid with fetal cells. Both support diagnostic karyotype, CMA, and molecular assays. CVS mosaicism may be confined to placenta—often prompting amnio follow-up . Quote modern, lower procedure-related loss estimates rather than outdated one-size historical percentages, and always frame residual diagnostic limits.

Domain 3C tests whether you can choose the right procedure for gestational age and question, counsel mosaicism after CVS, and communicate risk without scare tactics or false precision.

Procedure Comparison

Feature CVS Amniocentesis

Typical timing ~10–13 weeks’ gestation ~15–18+ weeks (earlier amnio historically associated with higher risk—avoid outdated early-amnio practices in counseling)

Sample Chorionic villi (placental trophoblast/mesenchyme depending on processing) Amniotic fluid (fetal cells shed into fluid; also AFP/AChE for ONTD in some protocols)

Earliest diagnostic answer Earlier in pregnancy Later than CVS

Key biologic caveat Confined placental mosaicism ; maternal cell contamination risk if not carefully processed Generally better reflection of fetal genotype for chromosomal mosaicism questions; culture failure possible

Common test menu Karyotype, CMA, targeted molecular testing, sometimes rapid aneuploidy tests Same chromosomal/molecular menu; fluid AFP for open NTD assessment when indicated

Transcervical vs transabdominal CVS and ultrasound-guided amniocentesis are technical routes chosen by the operator based on placenta location, gestation, and anatomy—counselors explain that approach is individualized.

What “Diagnostic” Still Does Not Mean

Even after CVS/amnio:

The assay ordered must match the question (karyotype vs CMA vs single-gene test).

Mosaic results require nuanced interpretation (true fetal mosaicism vs culture artifact vs CPM).

Normal chromosomes do not exclude non-genetic disease or untested single-gene conditions.

Maternal cell contamination can rarely confound molecular results—labs use identity markers when indicated.

Miscarriage and Complication Risk: Historical vs Modern Framing

Older teaching often quoted approximate excess miscarriage risks near 1% for CVS and 0.5% for amniocentesis . Contemporary evidence and society guidance generally support lower procedure-related loss rates in experienced centers—commonly discussed in ranges well under 1%, sometimes on the order of roughly 1 in several hundred to ~1 in 1,000 , varying by study design, background loss rates, operator experience, and indication. Exact figures shift with literature updates; the exam-relevant skill is:

Do not present historical round numbers as immutable universal truth.

Distinguish background miscarriage risk at that gestation from attributable procedure risk .

Note that risk is operator- and center-dependent .

Include other complications in consent: bleeding, infection, membrane rupture, Rh sensitization (offer RhIG when indicated), and—for CVS—historical concerns about limb reduction with very early CVS (practice moved timing later to mitigate).

Framing error Better counseling

“CVS causes miscarriage 1% of the time in everyone” “Older estimates were higher; current experienced-center risks are lower; your background risk also matters”

“Amnio is always twice as safe as CVS” Compare timing needs, mosaicism issues, and local outcome data—not a slogan

  • Ignoring background loss Many early losses occur with or without procedures
  • Confined Placental Mosaicism After CVS

CPM = chromosomal mosaicism in the placenta with a different (often normal) fetal karyotype. Because CVS samples placenta, mosaic or aneuploid CVS results may not represent the fetus.

Counseling algorithm (conceptual):

Explain that villi are placental tissue.

Review whether mosaicism involves a chromosome associated with viable fetal mosaicism syndromes vs likely culture/CPM patterns (specialist interpretation).

Offer amniocentesis for a fetal-cell-source karyotype/CMA when clarification is needed.

Consider uniparental disomy (UPD) studies for certain chromosomes when mechanisms involve trisomy rescue (condition-specific—e.g., concerns for imprinted chromosomes).

Coordinate detailed ultrasound and, if appropriate, postnatal confirmation plans.

Worked scenario. CVS karyotype shows mosaic trisomy 20. Amniocentesis is euploid and anatomy survey is normal. Counseling emphasizes likely CPM, residual low-level fetal mosaicism that cannot be entirely excluded, and postnatal pediatric awareness—without equating the CVS mosaic result to a definitive fetal diagnosis.

Contrast with NIPT: both NIPT and CVS are placenta-facing in different ways; amniocentesis is often preferred to resolve placenta–fetus discordance.

Choosing CVS vs Amniocentesis in Vignettes

Clinical priority Lean toward

Need earliest possible diagnostic genotype (e.g., known familial variant, early decision timeline) CVS, if timing eligible and lab can run the assay on villi

  • Clarifying possible CPM / discordant NIPT / mosaic CVS Amniocentesis
  • Concurrent ONTD biochemical assessment on fluid Amniocentesis (AFP/AChE pathways)
  • Placenta inaccessible for CVS / contraindication Amniocentesis at appropriate gestation

Patient declines all invasive testing Respect; offer non-invasive screening and ultrasound pathway with clear residual-risk language

Informed Consent Elements for GCs

Before referral or in co-counseling with MFM:

  • Indication and expected yield
  • Alternatives: no invasive test; screening only; waiting for postnatal testing
  • Procedure steps in plain language
  • Risk framing (modern estimates + uncertainty)
  • Result timelines and possible uncertain/mosaic outcomes
  • RhIG and infection precautions as applicable

Psychosocial preparedness for results that may lead to continuation, specialized perinatal care, or pregnancy termination decisions

Exam trap: Presenting invasive testing as mandatory after any positive screen. The ethical and clinical standard is offer , with informed decline documented.

Master timing + tissue source + CPM follow-up + modern risk framing —those four pillars cover nearly all CVS/amnio board items.